In 2018, the SOLO-1 trial randomized 391 patients with BRCA1 and/or BRCA2 mutation, FIGO Stage III or IV high-grade serous or endometrioid ovarian/primary peritoneal/fallopian tube cancer, regardless of surgical outcome and/or complete/partial response after first-line platinum-based chemotherapy. Here, BRCA2 is linked to fallopian tube cancer.